ERBB2 and breast cancer: Another interesting study targeted 17q23 amplicon using a systemically delivered RNA-laden chitosan-based NPs capable of codelivery of GSK2830371 (WIP1 inhibitor), and antagomiR21 is reported to overcome the resistance to anti-HER2 therapy in the HER2+ breast cancer model.